ValuEngine upgraded shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from a sell rating to a hold rating in a research report report published on Friday.

Several other brokerages also recently weighed in on ORMP. HC Wainwright reaffirmed a buy rating and set a $25.00 target price on shares of Oramed Pharmaceuticals in a research note on Wednesday, November 22nd. B. Riley reiterated a buy rating and set a $20.00 price target on shares of Oramed Pharmaceuticals in a report on Monday, December 11th.

Shares of Oramed Pharmaceuticals (ORMP) traded up $0.11 on Friday, reaching $9.11. 46,548 shares of the company traded hands, compared to its average volume of 53,100. Oramed Pharmaceuticals has a 1 year low of $5.85 and a 1 year high of $11.34. The stock has a market cap of $128.76, a P/E ratio of -11.53 and a beta of 0.34.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Susquehanna International Group LLP acquired a new position in Oramed Pharmaceuticals during the 3rd quarter worth approximately $185,000. Virtu KCG Holdings LLC acquired a new position in Oramed Pharmaceuticals during the 2nd quarter worth approximately $125,000. Finally, Wells Fargo & Company MN grew its holdings in Oramed Pharmaceuticals by 4.4% during the 2nd quarter. Wells Fargo & Company MN now owns 14,725 shares of the biotechnology company’s stock worth $114,000 after acquiring an additional 625 shares in the last quarter. Institutional investors own 1.92% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Oramed Pharmaceuticals (ORMP) Upgraded by ValuEngine to Hold” was posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.

Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with's FREE daily email newsletter.